Gandiga, Prateek C. http://orcid.org/0000-0003-1635-8974
Ghetie, Daniela
Anderson, Elizabeth
Aggrawal, Rohit
Article History
Accepted: 28 April 2023
First Online: 1 June 2023
Declarations
:
: PCG notes the following disclosures: (1) Kezar Pharmaceuticals [Consultant]. DG notes the following disclosures: (1) Revolo Biotherapeutics [Consultant]. RA notes the following disclosures: (1) Mallinckrodt [Consultant, Research grant], (2) Octapharma [Consultant], (3) CSL Behring [Consultant], (4) Bristol Myers-Squibb [Consultant, Research grant], (5) EMD Serono [Consultant, Research grant], (6) Q32 [Research grant], (7) Kezar [Consultant], (8) Pfizer [Consultant, Research grant], (9) AstraZeneca [Consultant], (10) Alexion [Consultant], (11) Argenx [Consultant], (12) Boehringer Ingelheim (BI) [Consultant, Research grant], (13) Corbus [Consultant], (14) Janssen [Consultant, Research grant], (15) Kyverna [Consultant], (16) Roivant [Consultant], (17) Merck [Consultant], (18) Galapagos [Consultant], (19) Actigraph [Consultant], (20) Scipher [Consultant], (21) Horizon Therapeutics [Consultant], (22) Teva [Consultant], (23) Beigene [Consultant], (24) ANI Pharmaceuticals [Consultant], (25) Biogen [Consultant], (26) Nuvig [Consultant], (27) Capella Bioscience [Consultant], (28) CabalettaBio [Consultant]. EA has no external relationships to disclose.
: This article does not contain any studies with human or animal subjects performed by any of the authors.